Fundraising FoxSano Chemicals
Bryan, US · Texas corporation
Find your way into Sano Chemicals
Sign up to see every warm intro you have to Sano Chemicals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Sano Chemicals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Sano Chemicals is a clinical-stage drug development company creating new chemical entities (NCEs) as first-in-class treatments for antimicrobial-resistant fungi and bacteria, with additional research into cancer applications. It develops novel drug products aimed at infectious diseases where existing treatments have become ineffective.
Founders & leadership
Reported raises · per SEC filings
Form D private placements$1.1M disclosed across 2 rounds · 2024
▶$350KraisedMay 2024 · 1 investors · OtherRule 506(b)
- Frank AustinDirector
- Stephen PruettDirector
- Timothy HieberyDirector
- James SmithExecutive Officer
- Shi-En LuDirector
- Amount sold
- $350K
- Placement agents
- Elizabeth Hiebert
- First sale
- Apr 2024
- Incorporated
- Corporation, Texas
- Federal exemptions
- 06b
▶$710KraisedJan 2024 · 1 investors · BiotechnologyRule 506(b)
- James Leif SmithExecutive Officer
- Offering amount
- $710K
- Amount sold
- $710K
- Minimum investment
- $100K
- Proceeds to insiders
- $710K
- First sale
- Jan 2024
- Incorporated
- Corporation, Texas
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as Sano Chemicals.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2020 | $233.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2019 | $2.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2017 | $224.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2016 | $529.6K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Sano Chemicals do?
- Sano Chemicals is a clinical-stage drug development company creating new chemical entities (NCEs) as first-in-class treatments for antimicrobial-resistant fungi and bacteria, with additional research into cancer applications. It develops novel drug products aimed at infectious diseases where existing treatments have become ineffective.
- How much funding has Sano Chemicals raised?
- Sano Chemicals has disclosed $1.1M raised across 2 rounds.
- Where is Sano Chemicals headquartered?
- Sano Chemicals is headquartered in Bryan, US.